Conference Call with Anupam Rasayan India Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Anupam Rasayan India announced Q3FY25 results Total revenue for Q3FY25 was at Rs 3,866 million as compared to Rs 2,979 million in Q3FY24; up 30% YoY. EBITDA (incl. other income) was at Rs 1,208 million in Q3FY25 as compared to Rs 815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter. Profit After Tax was at Rs 542 million in Q3FY25 as compared to Rs 260 million in Q3FY24; up 108% YoY. Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market." "With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26. Result PDF
Conference Call with Anupam Rasayan India Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Anupam Rasayan India announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total revenue for Q2FY25 was at Rs 2,959 million as compared to Rs 3,956 million in Q2FY24. EBITDA (incl. other income) was at Rs 824 million in Q2FY25 as compared to Rs 1,109 million in Q2FY24, this would translate into 28% EBITDA margin in this quarter. Profit After Tax was at Rs 306 million in Q2FY25 as compared to Rs 487 million in Q2FY24. H1FY25 Financial Highlights: Total revenue for H1FY25 was at Rs 5,562 million as compared to Rs 7,944 million in H1FY24. EBITDA (incl. other income) was at Rs 1,416 million in H1FY25 as compared to Rs 2,247 million in H1FY24, this would translate into 25% EBITDA margin in H1FY25. Profit After Tax was at Rs 428 million in H1FY25 as compared to Rs 1,009 million in H1FY24. Anand Desai, Managing Director, Anupam Rasayan said: "In Q2FY25, we were nearing the end of a demand slump in the Agro segment, and we are now seeing a good recovery. The Pharma and Polymer segments, meanwhile, have been showing robust growth, fuelled by the launch of over 17 new molecules in FY24 and 3 additional molecules in H1FY25. As these products gain traction, we expect their contribution to grow. Additionally, the planned launch of more than 3 new molecules in the coming months should further accelerate growth in these areas. Our consolidated operating revenue for the quarter was Rs 294 crores, representing a QoQ growth of 14%, with a stable EBITDA margin of 28% in Q2FY25. We anticipate revenue to normalize as volumes increase in the latter half of the year. With the new capacity, scaling of recently launched fluorinated molecules, and signed LOIs and contracts, we are optimistic about strong growth over the medium term." Result PDF
Conference Call with Anupam Rasayan India Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.